Treatment of postmenopausal osteoporosis

British Medical Journal

Volumn 327, Issue 7411, 2003, Pages 355-356

  Cranney, A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; VITAMIN D;

BONE REMODELING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG POTENCY; ECONOMIC ASPECT; EDITORIAL; HEALTH CARE COST; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INJECTION; META ANALYSIS; MORTALITY; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTECTIVE CLOTHING; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; VERTEBRA FRACTURE;

EID: 0042733055     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7411.355     Document Type: Editorial

References (14)

1. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
2. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-9.
3. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:801-9.
4. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.
5. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003;14:2-12.
6. Crannev A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.
7. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.
8. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
9. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997;337:670-6.
10. Trivedi DP, Doll R, Tee Khaw K. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2002;326:469.
11. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
12. Van Schoor NM, Smit JH, Twisk JWR, Bouter LM, Lips P. Prevention of hip fractnres by external hip protectors a randomized controlled trial. JAMA 2003;289:1957-62.
13. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, Lacroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;12:281-9.
14. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, et al, for the Fracture Intervention Trial Research Group. Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial. Arch Intern Med 1997;157:2617-24.